Skip to main content
. 2020 Sep 17;10(3):132. doi: 10.3390/jpm10030132

Table 4.

Prediction of tumor response to NAC using MTVcsc in HER2-positive and TN subtypes with various NAC regimens.

Anthracycline and Taxane
Based (N = 57)
Taxane
Based (N = 18)
Anthracycline
Based (N = 7)
pCR (N = 16) Residual
Tumor (N = 41)
pCR (N = 6) Residual
Tumor (N = 12)
pCR (N = 0) Residual
Tumor (N = 7)
MTVcsc < 1.75 cm3 16 14 6 5 0 2
MTVcsc > 1.75 cm3 0 27 0 7 0 5
Prediction accuracy 75% (43/57) 72% (13/18) 71% (5/7)
with Anti-HER2
NAC (N = 31)
without Anti-HER2
NAC (N = 26)
pCR (N = 12) Residual
Tumor (N = 19)
pCR (N = 4) Residual
Tumor (N = 22)
MTVcsc < 1.75 cm3 12 5 4 13
MTVcsc > 1.75 cm3 0 14 0 9
Prediction accuracy 84% (26/31) 50% (13/26)